Journal Publications
Project Data Sphere's success is ultimately measured by the practice-changing scientific insights discovered by the research community. We are proud to share the following list of peer-accepted publications, and we are grateful to the data providers, research scientists, and patients that make this possible.
| Author(s) | Date |
Article Title |
Journal |
|---|---|---|---|
|
Steven B.Cohen, Jennifer Unangst, Feng Yu |
November 2020 | Enhancing the analytic utility of clinical trial data to inform health disparities research | Contemporary Clinical Trials Communications |
|
Teemu D. Laajala, Mika Murtojārvi, Arho Virkki, Tero Aittokalio |
June 2018 | ePCR: An R-package for Survival Time and Time-to-Event Prediction in Advanced Prostate Cancer, Applied to Real-World Patient Cohorts | Bioinformatics |
|
Hiroyuki Saeki, Takuji Komeda, Risa Tanaka, Yuki Yamatani & Hironori Sakai |
March 2022 | Estimation of a Suitable Number of Patients for Selective Safety Data Collection (ICH E19 Draft Guideline): When is the Safety Profile of a Drug Well Characterized? | Therapeutic Innovation & Regulatory Science |
|
Julia Wilkerson, Kald Abdallah, Charles Hugh-Jones, Greg Curt, Mace Rothenberg, Ronit Simantov, Martin Murphy, Joseph Morrell, Joel Beetsch, Daniel J. Sargent, Howard I. Scher, Peter Lebowitz,, Richard Simon, Wilfred D. Stein, Susan E. Bates, Tito Fojo |
January 2017 | Estimation of Tumour Regression and Growth Rates During Treatment in Patients with Advanced Prostate Cancer: A Retrospective Analysis | The Lancet Oncology |
|
Julia Wilkerson, Kald Abdallah, Charles Hugh-Jones, Greg Curt, Mace Rothenberg, Ronit Simantov, Martin Murphy, Joseph Morrell, Joel Beetsch, Daniel J. Sargent, Howard I. Scher, Peter Lebowitz, Richard Simon, Wilfred D. Stein, Susan E. Bates, Tito Fojo |
December 2016 | Estimation of Tumour Regression and Growth Rates During Treatment in Patients with Advanced Prostate Cancer: A retrospective Analysis | Lancet Oncology |
|
Kelsey H Natsuhara, Li Zhang, Christopher A Carlos, Hala T Borno |
April 2021 | Evaluating predictors of renal injury with sorafenib in hepatocellular carcinoma: A multi-ethnic cohort study | Journal of Onco-Nephrology |
|
Xiang Yin, Pallavi S. Mishra-Kalyan, Rajeshwari Sridhara, Mark D. Stewart,Elizabeth A. Stuart, and Ruthanna C. Davi |
January 2022 | Exploring the Potential of External Control Arms created from Patient Level Data: A case study in non-small cell lung cancer | Journal of Biopharmaceutical Statistics |
|
Amita Puranik, Prajakta Dandekar, Ratnesh Jain |
August 2022 | Exploring the potential of machine learning for more efficient development and production of biopharmaceuticals | AIChE Biotechnology Progress |
|
Omar Abdel-Rahman, Winson Y. Cheung |
January 2018 | External validation of the prostascore model inpatients with metastatic hormone-sensitive prostate cancer recruited to the CHAARTED study | BJU International |
|
Daniel Caldeira, Beatriz Nogueira-Garcia, Ana Abreu & Fausto J. Pinto |
December 2022 | Fish intake and risk of cardiovascular events: an analysis of the VITAL cohort | European Journal of Clinical Nutrition |
|
Timothe Menard, Bjorn Koneswarakantha, Donato Rolo, Yves Barmaz, Leszek Popko, Rich Bowling |
December 2019 | Follow‑Up on the Use of Machine Learning in Clinical Quality Assurance: Can We Detect Adverse Event Under‑Reporting in Oncology Trials? | Drug Safety |
|
Sophia Z Shalhout, Farees Saqlain, Kayla Wright, Oladayo Akinyemi, David M Miller |
January 2022 | Generalizable EHR-R-REDCap pipeline for a national multi-institutional rare tumor patient registry | Jamia Open |
|
Sebastian Pölsterl, Pankaj Gupta, Lichao Wang, Sailesh Conjeti, Amin Katouzian, Nassir Navab |
July 2017 | Heterogeneous ensembles for predicting survival of metastatic, castrate-resistant prostate cancer patients | F1000 Research |
|
Saskia Litière, Jan Bogaerts |
November 2022 | Imaging endpoints for clinical trial use: a RECIST perspective | Journal for ImmunoTherapy of Cancer |
